Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Tiziana Life Sciences Ltd (TLSA)

0.6242   -0.006 (-0.92%) 11-28 09:30
Open: 0.5957 Pre. Close: 0.63
High: 0.6665 Low: 0.6242
Volume: 8,222 Market Cap: 64(M)

Technical analysis

as of: 2022-11-28 9:22:19 AM
Stoxline posted a BUY today, same as yesterday. Upward movement continues.
Target: Six months: 0.78     One year: 0.86
Support: Support1: 0.57    Support2: 0.47
Resistance: Resistance1: 0.67    Resistance2: 0.74
Pivot: 0.65
Moving Average: MA(5): 0.63     MA(20): 0.66
MA(100): 0.73     MA(250): 0.82
MACD: MACD(12,26): -0.1     Signal(9): -0.1
Stochastic oscillator: %K(14,3): 43.4     %D(3): 41.1
RSI: RSI(14): 41.3
52-week: High: 1.37  Low: 0.52
Average Vol(K): 3-Month: 55 (K)  10-Days: 41 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ TLSA ] has closed above bottom band by 22.5%. Bollinger Bands are 31% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 0.66 - 0.67 0.67 - 0.67
Low: 0.59 - 0.59 0.59 - 0.59
Close: 0.62 - 0.63 0.63 - 0.64

Company Description

Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti-Interleukin 6 receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation and to treat COVID-19 patients. The company was incorporated in 1998 and is headquatered in London, the United Kingdom.

Headline News

Wed, 23 Nov 2022
Tiziana (TLSA) Announces Article on Intranasal Administration of Foralumab Demonstrating Modulated Effector CD8+ T cell Function, Induced T Cell Regulatory Response in Human Subjects -

Thu, 10 Nov 2022
Tiziana Life Sciences Announces Near-Term Strategic Focus on Intranasal Foralumab for Diseases of the Central Nervous System (CNS) - Yahoo Finance

Wed, 09 Nov 2022
Depression and anxiety during the first and second waves of the COVIDÔÇÉ19 pandemic in two large, prospective, aging cohorts in rural and urban India - Wiley

Thu, 03 Nov 2022
Extending into Alzheimers (NASDAQ:TLSA) - Preview - Proactive Investors UK

Wed, 12 Oct 2022
Tiziana Life Sciences (TLSA) Stock: Why It Increased Over 15% Today - Pulse 2.0

Wed, 21 Sep 2022
Tiziana Life Sciences (TLSA) Stock: Why It Increased 9.87% Today - Pulse 2.0

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 102 (M)
Shares Float 58 (M)
% Held by Insiders 43 (%)
% Held by Institutions 5.2 (%)
Shares Short 80 (K)
Shares Short P.Month 101 (K)

Stock Financials

EPS -0.24
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0.4
Profit Margin (%) 0
Operating Margin (%) 0
Return on Assets (ttm) -28.7
Return on Equity (ttm) -45.2
Qtrly Rev. Growth 0
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -0.27
Qtrly Earnings Growth 0
Operating Cash Flow -22 (M)
Levered Free Cash Flow -13 (M)

Stock Valuations

PE Ratio -2.64
PEG Ratio 0
Price to Book value 1.57
Price to Sales 0
Price to Cash Flow -2.97

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.